

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 February 2022 (10.02.2022)



(10) International Publication Number
WO 2022/031234 A1

(51) International Patent Classification:
G01N 33/50 (2006.01)

(21) International Application Number:
PCT/SG2021/050458

(22) International Filing Date:
04 August 2021 (04.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10202007446W 04 August 2020 (04.08.2020) SG

(71) Applicant: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG).

(72) Inventors: **BLERIOT, Camille**; c/o Singapore Immunology Network, 8A Biomedical Grove, #03-06 Immunos, Singapore 138648 (SG). **GINHOUX, Florent**; c/o Singapore Immunology Network, 8A Biomedical Grove, #03-06 Immunos, Singapore 138648 (SG). **SHARMA, Ankur**; c/o Genome Institute of Singapore, 60, Genome, Biopolis Street, Singapore 138672 (SG).

(74) Agent: **DONALDSON & BURKINSHAW LLP**; 24 Raffles Place, #15-00 Clifford Centre, Singapore 048621 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: CHARACTERISING MACROPHAGES AND METHODS THEREOF

(57) Abstract: There is provided a method of characterising a macrophage in a tissue of a subject, wherein the method comprises determining an expression of one or more biomarkers in the macrophage, wherein the one or more biomarkers is selected from the group consisting of Fcrl2, Serpina5, Nid2, Slc27a6, Sema5a, Cdh13, Bcl6b, C6, Klfl5, Marco, Cd209d, Tshz3, Bmprla, Tln2, Coro2b, Ackr2, 1110046J04Rik, Pcdhac2, Gm2253, Vsig4, Phactrt, NpM, CpneS, Angptl7, Gm26714, Aut52, Cxcl13, Sgce, 2900052N01 Rik, Cd209b, Timd4, Cd209g, Mrd (CD206), Spp1, Il22ra2, Gm24112, Gm23010, Ighv7-1, Gm23628, Gm24620, Gm23058, Arhgef37, Gad1-ps, Gm26397, Ighv2-5, Chil3, Mir1934, 1810012K08Rik, Ighv1 -59, Gm14119, Gm19620 and Snord71. In one embodiment, the macrophage can be an embryo-derived macrophage and/or a long-lived tissue resident macrophage. In another embodiment, the macrophage can be a monocyte-derived macrophage. Also disclosed are methods of diagnosing a disease in a subject, methods of treating a disease, and kits for use thereof relating to a macrophage determined to express one or more of the said biomarkers.



WO 2022/031234 A1